Article Information
History
- September 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Joseph D Challenger1,§,*,
- Stijn W van Beek2,§,
- Rob ter Heine2,
- Saskia C van der Boor3,
- Giovanni D Charles1,
- Merel J Smit3,
- Chris Ockenhouse4,
- John J Aponte4,
- Matthew BB McCall3,
- Matthijs M Jore3,
- Thomas S Churcher1,° and
- Teun Bousema3,°
- 1Medical Research Council Centre for Global Infections Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom
- 2Radboud university medical center, Radboud Institute for Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands
- 3Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- 4PATH Malaria Vaccine Initiative, Washington DC, USA
- ↵*Corresponding author, email: j.challenger{at}imperial.ac.uk
↵§,° Contributed equally
Posted September 14, 2022.
Combatting seasonal malaria transmission using a highly potent Plasmodium falciparum transmission-blocking monoclonal antibody
